Katlyn Nemani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Katlyn Nemani has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Xiaoduo Fan
Psychotic Disorders Program, UMass Memorial Medical Center, University of Massachusetts Medical School, Worcester, MA, United States
2 shared publications - Aaron M. Ring
Division of Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA, USA
1 shared publication - Adrienne Carol Lahti
Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, USA
1 shared publication - Alison Figueroa Almeda
Division of Oncology Department of Medicine Stanford University School of Medicine 94305 Stanford CA United States
1 shared publication Andrea Origoni
Department of Psychology, Sheppard Pratt, Baltimore, MD, USA
1 shared publication- Benjamin Schuman
Department of Neuroscience and Physiology, New York University Langone Medical Center, New York, USA
1 shared publication
Latest Publications
- Open Access
High prevalence of CNS-directed autoantibodies in patients with schizophrenia
Schizophrenia is a severe neuropsychiatric disorder whose etiology and biological heterogeneity remain poorly understood. Immune dysregulation has long been implicated, but the breadth and clinical significance of autoantibody responses remain unclear beyond rare individual examples. Here we use Rapid Extracellular Antigen Profiling–a proteome-scale assay for autoantibodies against extracellular and secreted proteins–to profile 352 individuals with schizophrenia and 971 community controls. We find that schizophrenia is marked by a striking elevation in extracellular autoantibody burden, present near disease onset, and approaching nearly twice control levels in the most severely ill patients. This burden increases with age in a pattern that diverges from controls and targets central nervous system antigens, including neuroactive receptors, neuronal ion channels, proteins involved in synaptic function, and blood–brain barrier integrity. Autoantibodies against blood–brain barrier antigens impair barrier function ex vivo and are associated with broader central nervous system autoreactivity, supporting a model in which barrier disruption promotes loss of tolerance to brain antigens. At the clinical level, higher baseline autoantibody burden predicts reduced responsiveness to the antipsychotic risperidone, suggesting that autoantibodies contribute to treatment resistance. Together, these findings identify humoral autoimmunity as a pervasive component of schizophrenia and imply that therapies that reset humoral immunity or reduce autoantibody burden may benefit patients beyond those with currently recognized antibody-mediated syndromes. GRAPHICAL
Open AccessHigh prevalence of CNS-directed autoantibodies in patients with schizophrenia
Schizophrenia is a severe neuropsychiatric disorder whose etiology and biological heterogeneity remain poorly understood. Immune dysregulation has long been implicated, but the breadth and clinical significance of autoantibody responses remain unclear beyond rare individual examples. Here we use Rapid Extracellular Antigen Profiling–a proteome-scale assay for autoantibodies against extracellular and secreted proteins–to profile 352 individuals with schizophrenia and 971 community controls. We find that schizophrenia is marked by a striking elevation in extracellular autoantibody burden, present near disease onset, and approaching nearly twice control levels in the most severely ill patients. This burden increases with age in a pattern that diverges from controls and targets central nervous system antigens, including neuroactive receptors, neuronal ion channels, proteins involved in synaptic function, and blood–brain barrier integrity. Autoantibodies against blood–brain barrier antigens impair barrier function ex vivo and are associated with broader central nervous system autoreactivity, supporting a model in which barrier disruption promotes loss of tolerance to brain antigens. At the clinical level, higher baseline autoantibody burden predicts reduced responsiveness to the antipsychotic risperidone, suggesting that autoantibodies contribute to treatment resistance. Together, these findings identify humoral autoimmunity as a pervasive component of schizophrenia and imply that therapies that reset humoral immunity or reduce autoantibody burden may benefit patients beyond those with currently recognized antibody-mediated syndromes. GRAPHICAL
- Open Access
- 3 June 2024
- Published by Elsevier in Brain, Behavior, & Immunity - Health
- Vol. 38, 100802
Anti-spike antibody responses to SARS-CoV-2 mRNA vaccines in people with schizophrenia and schizoaffective disorder
- 3 June 2024
- Published by Elsevier in Brain, Behavior, & Immunity - Health
- Vol. 38, 100802
Open AccessAnti-spike antibody responses to SARS-CoV-2 mRNA vaccines in people with schizophrenia and schizoaffective disorder
- 1 December 2019
- Published by Longdom Group in Clinical Schizophrenia & Related Psychoses
- Vol. 12 (4) , 168-176
Clozapine, Diabetes Mellitus, Cardiovascular Risk and Mortality: Results of a 21-Year Naturalistic Study in Patients with Schizophrenia and Schizoaffective Disorder
The goal of this 21-year naturalistic study of clozapine treated patients was to examine the cardiovascular risk factors following clozapine initiation and resultant mortality estimates from cardiovascular disease. Data was collected from medical records of clozapine treated patients with schizophrenia or schizoaffective disorder from January 1992 to February 2012. Demographics, clozapine dosage and laboratory results were extracted at 12-month intervals. At clozapine initiation, the mean age of 96 patients was 36.4 years ±7.6 years; N=27(28%) were women. The mean duration of clozapine use was 13 years. The Kaplan-Meier estimate for 21-year cardiovascular events was 29%, while the Kaplan-Meier estimate for 21-year mortality from cardiovascular disease was 10%. The mean cardiovascular risk increased during the first ten years (p<.01), while a slight decrease occurred beyond ten years (p<.01). Patients involved in cardiometabolic research showed a greater decrease in cardiovascular risk factors ove...
- 1 December 2019
- Published by Longdom Group in Clinical Schizophrenia & Related Psychoses
- Vol. 12 (4) , 168-176
Clozapine, Diabetes Mellitus, Cardiovascular Risk and Mortality: Results of a 21-Year Naturalistic Study in Patients with Schizophrenia and Schizoaffective Disorder
The goal of this 21-year naturalistic study of clozapine treated patients was to examine the cardiovascular risk factors following clozapine initiation and resultant mortality estimates from cardiovascular disease. Data was collected from medical records of clozapine treated patients with schizophrenia or schizoaffective disorder from January 1992 to February 2012. Demographics, clozapine dosage and laboratory results were extracted at 12-month intervals. At clozapine initiation, the mean age of 96 patients was 36.4 years ±7.6 years; N=27(28%) were women. The mean duration of clozapine use was 13 years. The Kaplan-Meier estimate for 21-year cardiovascular events was 29%, while the Kaplan-Meier estimate for 21-year mortality from cardiovascular disease was 10%. The mean cardiovascular risk increased during the first ten years (p<.01), while a slight decrease occurred beyond ten years (p<.01). Patients involved in cardiometabolic research showed a greater decrease in cardiovascular risk factors ove...
- 1 January 2015
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 56, 155-160
Schizophrenia and the gut–brain axis
- 1 January 2015
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 56, 155-160
Schizophrenia and the gut–brain axis
- Open Access
- 1 January 2014
- Published by Springer Nature in Behavioral and Brain Functions
- Vol. 10 (1) , 35
Fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia
Obesity induced by antipsychotics severely increases the risk of many diseases and significantly reduces quality of life. Genome Wide Association Studies has identified fat-mass and obesity-associated (FTO) gene associated with obesity. The relationship between the FTO gene and drug-induced obesity is unclear.
- 1 January 2014
- Published by Springer Nature in Behavioral and Brain Functions
- Vol. 10 (1) , 35
Open AccessFat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia
Obesity induced by antipsychotics severely increases the risk of many diseases and significantly reduces quality of life. Genome Wide Association Studies has identified fat-mass and obesity-associated (FTO) gene associated with obesity. The relationship between the FTO gene and drug-induced obesity is unclear.